Summary & Overview
HCPCS J9181: Injection, etoposide, 10 mg
HCPCS Level II code J9181 designates an injection of etoposide in 10 mg units, used to bill for the drug component of chemotherapy administration. Etoposide is a commonly used cytotoxic agent in oncology care, and standardized HCPCS reporting for drug units is important for consistent billing, reimbursement processing, and national spending analysis. This code matters nationally because injectable oncology drugs constitute a substantial portion of outpatient drug spending and require precise unit-based reporting for clinical and financial tracking.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise orientation to clinical context and typical sites of service for J9181, along with benchmark and coverage perspectives for major national payers. The publication includes unit-billing considerations, common modifier usage (listed elsewhere in the document), and comparisons to related oncology drug codes where applicable.
The content provides operational clarity for revenue cycle and clinical billing teams: what the code represents, where it is commonly billed, and which national payers are in scope. Data elements not supplied in the input (such as payer-specific reimbursement rates, ICD-10 pairings, and taxonomies) are noted as unavailable in the input and are covered as gaps for readers to address with payer-specific policy lookup.
Billing Code Overview
HCPCS Level II code J9181 represents an injection of etoposide, 10 mg. This code is used to report the pharmaceutical administration of etoposide in a quantifiable unit of 10 mg.
Service Type: Intravenous or injectable chemotherapy agent administration
Typical Site of Service: Hospital outpatient, physician office, or infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with relapsed small cell lung cancer presents to the outpatient oncology infusion suite for systemic chemotherapy. The oncologist orders intravenous etoposide dosed per body surface area. Pharmacy prepares J9181 billed as "Injection, etoposide, 10 mg" and the infusion nurse verifies consent, performs baseline vital signs and laboratory review (CBC, renal and hepatic panel), establishes peripheral IV or accesses an implanted port, and administers the medication over the prescribed infusion duration. Typical workflow includes medication reconciliation, chemotherapy verification (two-person check), premedication as indicated (antiemetic), administration of J9181 units based on total dose, post-infusion monitoring for acute infusion reactions, documentation of lot number and units administered, and scheduling follow-up oncology visits and labs. The typical site of service is an outpatient hospital infusion center or freestanding oncology infusion clinic. Common clinical indications include small cell lung cancer, testicular cancer, and other solid tumors or hematologic malignancies where etoposide is part of multi-agent chemotherapy regimens.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service | When a separately identifiable service or procedure is performed on the same day as another service and not normally billed together |